Repligen Corp. Stock
Price
Target price
€125.80
€125.80
2.220%
2.75
2.220%
€158.80
03.10.25 / Tradegate
WKN: 870980 / Symbol: RGEN / Name: Repligen Corp / Stock / Pharmaceuticals / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Repligen Corp. Stock
Repligen Corp. gained 2.220% today.
We see a rather positive sentiment for Repligen Corp. with 17 Buy predictions and 1 Sell predictions.
As a result the target price of 158 € shows a positive potential of 25.6% compared to the current price of 125.8 € for Repligen Corp..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Repligen Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Repligen Corp. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
B****
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Repligen Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Repligen Corp. | 2.220% | 17.187% | 26.103% | -4.407% | -10.111% | -37.062% | -0.514% |
| Opko Health Inc. | -0.520% | 5.560% | 12.371% | -4.760% | -8.970% | -33.808% | -61.557% |
| Amicus Therapeutics Inc. | -1.520% | -7.801% | -2.985% | -31.217% | -28.962% | -38.189% | -44.444% |
| Hutchison China Meditech Ltd | 0.000% | 3.175% | 4.839% | -22.619% | 0.775% | 50.289% | -50.000% |
Comments
Repligen (NASDAQ:RGEN) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen (NASDAQ:RGEN) was given a new $150.00 price target on by analysts at HSBC Holdings plc. They now have a "buy" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen (NASDAQ:RGEN) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating. They now have a $155.00 price target on the stock, up previously from $130.00.
Show more
Ratings data for RGEN provided by MarketBeat
